Conference Calls and Earnings Call Transcripts for NSE and BSE Stocks

Conference Calls and Earnings Call Transcripts: Get insights into company performance, financials, capex plans for NSE and BSE Stocks

announcement
Conference/Earnings Calls Alerts
166.40
-2.32%
1151.50
-2.93%
10151.00
-3.58%
Dixon Technologies (India) Ltd - 540699 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …
BSE India
In furtherance to the intimation dated 13th May, 2025, whereby the Company had informed the Stock Exchanges that the Company had arranged a Conference Call for the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial year ended 31st March, 2025, on Tuesday, 20th May, 2025, and in compliance with the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Audio Recording of the Conference Call has been uploaded on our company's website and the same can be accessed at https://www.dixoninfo.com/json/dixon/quarterly-result/10032466.mp3
141.86
-3.27%
171.34
-1.49%
Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
BSE India
Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform the stock exchanges that the Company has uploaded the audio recording of investor(s) / analyst(s) meet for Q4FY25 financial performance and strategy update held today i.e. May 20, 2025 on the Company's website at http://marksanspharma.com/investors-meet.html
1858.80
-2.36%
1794.80
-1.50%
Conference Call with Gland Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
10151.00
-3.58%

Conference Call with Dixon Technologies (India) Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.

4369.20
0.83%
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.

Earnings Calls Podcast on